EMERGENT BIOSOLUTIONS INC. Deferred Revenue Recognized
EMERGENT BIOSOLUTIONS INC. (EBS) reported Deferred Revenue Recognized of $3.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $2.30M, a 76.92% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $1.30M.
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was -$24.00M.
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, revenue recognized for the quarter ending 2020-03-31 was $5.90M.
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, revenue recognized for fiscal 2025 was $3.20M, a 87.79% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, revenue recognized for fiscal 2024 was $26.20M, a 29.70% increase from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, revenue recognized for fiscal 2023 was $20.20M.
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, revenue recognized for fiscal 2019 was -$30.90M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.40M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $2.30M 10-Q · filed 2026-05-01 | |||
| 2025-12-31 | $3.20M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $2.10M 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $1.90M 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $1.30M 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $26.20M 10-K · filed 2025-03-04 | |||
| 2024-09-30 | $25.80M 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | -$25.00M 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | -$24.00M 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $20.20M 10-K · filed 2024-03-08 | |||
| 2023-09-30 | $7.30M 10-Q · filed 2023-12-11 | |||
| 2023-06-30 | $6.80M 10-Q · filed 2023-08-09 | |||
| 2020-09-30 | $69.00M 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $27.20M 10-Q · filed 2020-07-31 | |||
| 2020-03-31 | $5.90M 10-Q · filed 2020-05-01 | |||
| 2019-12-31 | -$30.90M 10-K · filed 2020-02-25 | |||
| 2019-09-30 | $18.10M 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $7.40M 10-Q · filed 2019-08-02 | |||
| 2019-03-31 | -$2.80M 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | -$29.10M 10-K · filed 2020-02-25 | |||
| 2018-09-30 | -$15.12M 10-Q · filed 2018-11-02 | |||
| 2018-06-30 | -$15.34M 10-Q · filed 2018-08-03 | |||
| 2018-03-31 | -$12.30M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |